Join us at the 2022 ASCO Annual Meeting
to discover NavDx® – the first and only clinically validated circulating
tumor-tissue–modified viral (TTMV®)-HPV DNA blood test.
Stop by booth #21152 to learn about the technology that
is transforming the management of HPV-driven cancers.
We invite you to attend the Oral Abstract Session
Head and Neck Cancer Track (S406)
Association of plasma tumor-tissue–modified viral (TTMV)-HPV DNA
with tumor burden, treatment type, and outcome:
A translational analysis from NRG-HN002 (#6006)
Friday, June 3, 4:45pm CDT
McCormick Place Convention Center
